Check for updates

The Effect of Non-Invasive Mechanical Ventilation on Respiratory and Inflammatory Parameters in Patients with Chronic Obstructive Pulmonary Disease

Mohammad Hashemian¹, Atefeh Fakharian^{1*}, Reyhaneh Zahiri¹, Esmaeil Mortaz² and Mohammad Reza Masjedi²

1. Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

2. Clinical Tuberculosis and Epidemiology Research Center, National Research and Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

* Corresponding author

Atefeh Fakharian, MD

Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran **Tel:** +98 21 2610 9991 **Fax:** +98 21 2712 2009 **Email:** fakharian_2005@yahoo.com

Received: Jan 6 2021 **Accepted:** Mar 27 2021

Citation to this article:

Hashemian M, Fakharian A, Zahiri R, Mortaz E, Masjedi MR. The Effect of Non-Invasive Mechanical Ventilation on Respiratory and Inflammatory Parameters in Patients with Chronic Obstructive Pulmonary Disease. *J Iran Med Counc.* 2021;4(2):80-5.

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) is an airway obstructive disease that is often caused by smoking. The disease is currently the third leading cause of death worldwide. The current therapeutic approach is based on Non-Invasive Ventilation (NIV) therapy, which can reduce mortality, the need for hospitalization in the intensive care unit, and to some extent therapeutic complications. Therefore, this study was performed to determine the effect of noninvasive ventilation along with routine treatments on respiratory markers, inflammation, and clinical status of patients with COPD.

Methods: A total of 30 patients with COPD referred to Masih Daneshvari Hospital were divided into control and intervention groups. In the intervention group, 15 patients underwent non-invasive ventilation in addition to the usual treatments, and in the control group, the patients underwent only the usual treatments. After completing the mMRC (Modified Medical Research Council) questionnaire and evaluating FEV1 (Forced Expiratory Value in one score), 5 ml of blood samples were taken from these patients at the beginning of the study, on the seventh to tenth day, and also in the third month, and the results of this evaluation were compared between the two groups.

Results: Based on the results of this study, the mMRC score of the intervention group was significantly lower than the control group in the first week (p=0.043) and three months after treatment (p=0.049). However, indices such as FEV1, and IL-8(Interleukin-8) did not change significantly in both groups.

Conclusion: The use of non-invasive mechanical ventilation along with standard treatments can play a relative role in improving patient outcomes.

Keywords: Chronic obstructive pulmonary disease, Interleukin-8, Non-invasive mechanical ventilation

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is an inflammatory disease of the airways that is more common in smokers. Genetics, air pollution, and respiratory infections that occur in childhood can also affect the risk of developing this disease (1). Inflammatory changes of COPD have transformed this disease from a limited disease to systemic inflammatory disease and in its pathogenesis, inflammatory changes and processes, cell proliferation, apoptosis, alteration of lung cell characteristics, and extracellular matrix regeneration have been identified (2,3). Exacerbation of COPD is associated with the presence of a combination of epithelial cells, acute and chronic inflammatory cells, as well as large numbers of neutrophils in the airway mucus. Also, in the inner layer of the airways, the thickness of the muscular layer is increased and mild and complex inflammatory infiltration is observed (4).In such cases, CD8+ T-cell, eosinophils, and neutrophils are found in the bronchial biopsy of these patients. Besides, signs of inflammation are visible in the areas around the bronchi, especially in people with chronic bronchitis (5,6). Also, airways smaller than 2 mm contain mucus and can lead to airway obstruction and FEV1 changes (7). Following smoking and exposure to other respiratory stimulants, inflammatory cells migrate to the lungs and airways. As a result, lung damage and impaired normal lung repair will be predictable (8). Neutrophils, eosinophils, macrophages, and lymphocytes are inflammatory cells produced in response to COPD (9,10). In patients with COPD, interleukin-8 levels also increase due to an increase in neutrophils (11,12). Interleukin-8 is produced by stimulation of smoking, TNFa, and LPS. This chemokine is a potent chemoattractant for neutrophils. Advanced COPD often occurs due to infection, and patients need routine treatments including the use of bronchodilators and inhaled and injectable steroidal anti-inflammatory drugs at various doses, besides other treatments to prevent hypoxemia and hypercarbia (13).

Non-Invasive Ventilation (NIV) can significantly reduce mortality, the need for intubation, treatment complications, and hospital stays. There are several types of this method, including bi-level Positive Airway Pressure (BiPAP) and Continuous Positive Air Pressure (CPAP) (14). In the present study, the effect of NIV treatment and specifically BiPAP was investigated in patients with COPD referred to Masih Daneshvari Hospital in Tehran before receiving treatment, 7 and 10 days later, and also 3 months after receiving treatment. This study aimed to evaluate the therapeutic effect of NIV on inflammatory factors and clinical parameters in these patients.

Materials and Methods

The present study was performed at Masih Daneshvari Hospital in Tehran with the ethical code of sbmu1. REC.1392.21. After obtaining written consent from patients, 30 patients with inclusion criteria (Diagnosis of COPD by a physician, knowledge of study conditions) were divided into two groups using a simple randomization based on codes assigned to each patient (Figure 1).

In the intervention group, patients underwent noninvasive ventilation in addition to common treatments, and in the control group, patients were evaluated by common treatments.

Exclusion criteria included the presence of other conditions associated with COPD, such as pleural effusion, tumor, evidence of pulmonary pneumonia, and pulmonary aspiration. After receiving 5 *ml* of blood samples, hospitalized patients were treated with BiPAP and routine COPD treatments. During hospitalization, respiratory tests, Body Mass Index (BMI), and PCO2 (Partial pressure of carbon dioxide) were evaluated and the gold stage was determined. Also, a clinical examination was performed and the patient's mMRC was recorded.

Patients in the intervention group (15 patients) received non-invasive ventilation during their hospitalization. After 10 days of hospitalization, with collection of 5 *ml*s of the blood sample, patients were discharged with instructions for use of O2 and BiPAP. Discharged patients underwent blood sampling again during the quarterly follow-up and were evaluated for IL-8 levels as well as the effectiveness of other treatments (BiPAP, inhaled corticosteroids, Atrovent, B2-agonist). In the control group, patients received only the common treatments.

The present study was analyzed using SPSS 16 (SPSS Inc, USA), taking into account the 95% confidence interval while the significance was <0.05 and the type




Figure 1. Consort diagram of study.

1 error was equal to 0.05. Quantitative variables were analyzed using univariate analysis of variance and qualitative variables were analyzed using Wilcoxon signed-rank test.

Results

In the present study, a total of 30 patients (15 patients in each group) with COPD referred to Masih Daneshvari Hospital were evaluated, in which 12 patients were male (p=0.990) (Consort flowchart). The mean age of patients in the control group was 67.8 ± 7.7 and in the intervention group was 65.1 ± 9.8 (p=0.400). Findings from the demographic information of patients in the two groups treated with NIV and the control group are shown in figure 2.

The mean of FEV1 in the first week of treatment was 42.9 ± 10.7 in the control group and 40.8 ± 10.1 in the intervention group and there was no significant difference (p=0.880). Also, the results obtained in the first week showed that the mean mMRC in the intervention group was significantly lower than the control group (2.7\pm0.82 vs. 3.3 ± 0.7) (p=0.043).

On the other hand, the level of serum interleukin-8 in the control group was $1409.3\pm306.7 \text{ mg/dl}$ and in the intervention group was $1425.4\pm473.8 \text{ mg/dl}$.

Volume 4 Number 2 Spring 2021

The mean difference of this variable in the two groups under study was not statistically significant (p=0.650). The values of these variables are shown in table 1.

Secondary outcome variables

Three months after the intervention, vital signs and FEV1 levels, mMRC scores, and serum IL-8 levels in both groups were assessed. Based on the findings of these evaluations, the mean systolic blood pressure in the control group was 135.3 ± 13.6 and in the intervention group was $124.3\pm8.8 \text{ mmHg}$ (p=0.020). Also, the mean diastolic blood pressure in the mentioned groups was 77.7 ± 5.0 and $78.0\pm7.3 \text{ mmHg}$, respectively (p= 0.790). The study of patients' heart rate showed that the mean of the control group was 73.5 ± 7.9 beats per minute and in the group treated with NIV was 73.3 ± 6.1 beats per minute.

Based on the data obtained from this study, the mean heart rate of patients in the intervention and control groups was not statistically significant (p=0.840). Also, the mean of breaths per minute in the control group was 15.2 ± 1.3 and in the intervention group was 15.0 ± 1.5 (p=0.650). Similar findings were observed in the evaluation of central temperature (p=0.410). The mean level of FEV1 in the control group in the




Figure 2. Comparison of the mean age of patients in the intervention group and the control group.

third month of treatment was 46.7 ± 12.6 and in the intervention group was 48.7 ± 14.0 (p=0.720).

The mean of mMRC in this evaluation period in the intervention group was significantly lower than the control group (2.1±0.82 *vs.* 2.7. 0.6) (p=0.049). Besides, the mean serum level of IL-8 in the third month in the control group was 149.8±294.7 *mg/dl* and in the intervention group was 124.7±420.1 *mg/dl* (p=0.060) (Table 1).

Discussion

The results of the present study showed that the use of non-invasive mechanical ventilation has a relative effectiveness in improving the condition of COPD patients compared to standard treatment without non-invasive mechanical ventilation. One-week and three-month follow-up in this study showed that the use of this treatment can significantly reduce the mMRC score and lead to improved respiratory conditions in these patients. However, the use of noninvasive ventilation has no significant effect on FEV1 levels, and interleukin-8 levels as an inflammatory factor.

Numerous studies and meta-analyses have shown that the use of NIV improves short-term outcome in patients (15). The evaluation performed in the present study also reveals the role of this treatment in improving the long-term outcome of COPD patients. However, many patients are unable to tolerate this treatment. Despite the results of this study, Struik et al in 2014 with a one-year follow-up showed that the use of NIV along with standard treatment has no role in improving the outcome of COPD such as mortality, hospitalization, dyspnea and long-term hypercapnia (16). Plant et al also stated that the use of NIV improves acidosis during the first 4 hours, but has no effect on the long-term outcome of patients (17). However, the results of some researches are consistent with the present study, as Confalonieri et al have shown that the use of NIV improves the short-term and long-term outcomes of patients with COPD (18). The reason for the difference in the results was due to the way the groups were selected in these studies.

Systemic inflammation is closely related to the

		Intervention group Mean ±SD	Control group Mean ±SD	p-value
Before the study	FEV1	36.9±9.1	37.3±9.4	0.921
	mMRC	4.23±1.1	4.01±0.9	0.720
	IL-8	1697±304.22	1630±279.25	0.570
First week	FEV1	40.8±10.1	42.9±10.7	0.880
	mMRC	2.7±0.82	3.3±0.7	0.043
	IL-8	1425±473.8	1409.3±306.7	0.650
After three months	FEV1	48.7±14.0	46.7±126	0.720
	mMRC	2.1±0.82	2.7±0.6	0.049
	IL-8	124.7±420.1	149.8±294.7	0.060

Table 1. Comparative study of FEV1, mMRC, and IL-8 before the study, in the first week and after three months from the beginning of the study

development and spread of comorbidity in COPD patients. Oxidative stress and inflammation of the respiratory tract are seen in patients with COPD. Migration of immune and inflammatory cells into the peripheral airways during COPD and increased levels of interleukin-8 in bronchoalveolar lavage fluid have been demonstrated (19). Inflammation is characterized as a dominant aspect in COPD by the presence of activated neutrophils and macrophages. This increases the level of inflammatory mediators such as interleukin-8 (20). Accordingly, the improvement of inflammation can be considered as a favorable prognostic factor. That is the reason for using serum interleukin-8 levels by researchers as the main evidence.

The present study showed that the serum level of this biomarker in the three months of follow-up did not differ significantly between the two groups treated with NIV and the control group. In this regard, Márquez-Martin *et al* showed in their research that the combination of exercise and the use of NIV can play a significant role in reducing the level of inflammatory factors such as interleukin-8. However, the use of NIV alone has little effect on the level of these biomarkers (21). Because exercise produces inflammatory factors, it can be concluded that NIV may increase elevated and high levels of inflammatory factors and may not have an effect on the average increase in these factors that occurs during COPD. Further studies in this field are required to support this finding. However, Paone et al in their study which aimed to investigate the role of long-term home use of NIV on the systemic inflammatory response in patients with COPD reported conflicting findings. The researchers have shown that long-term use of NIV increases interleukin-6 levels and tumor necrosis factor alpha (TNF-a) while decreasing interleukin-10 levels (22). The researchers did not study interleukin-8 levels. Interleukin-8 is evidence of innate immunity, and interleukin-6 and interleukin-10 are secreted more than B and T cells (Specific immunity). Therefore, comparing the present study with the findings of Paone et al's study is somewhat difficult. In general, the role of NIV therapy in patients' inflammatory response needs further investigation.

Conclusion

The findings of the present study showed that the use of non-invasive mechanical ventilation along with standard treatments can play a relative role in improving patient outcomes. Also, a one-week and three-month follow-up in this study showed that the use of this treatment had no effect on FEV1 levels and interleukin-8 levels as an inflammatory agent but could lead to an improvement in the mMRC score.

Conflict of Interest

There is no conflict of interest in this study.

References

1. Khoshkhabar M, Mirenayat M, Abedi M, Karimzade S, Rizehbandi M, Fakharian A. The effect of inspiratory muscle training on spirometry parameters of patients with chronic obstructive pulmonary disease. J Clinical Physiotherapy Research;5(1):e2.

2. Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 2012 Aug 1;122(8):2749-55.

3. Owen CA. Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2(4):373-85.

4. Rezaee A, Fakharian A, Ghorbani F, Idani E, Abedini A, Jamaati H. Comparison of high-flow oxygenation with noninvasive ventilation in COPD exacerbation: A crossover clinical trial. Clin Respir J 2021;15(4):420-9.

5. Freeman CM, Martinez CH, Todt JC, Martinez FJ, Han MK, Thompson DL, et al. Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. Respir Res 2015;16(1):94.

6. Zhu J, Mallia P, Footitt J, Qiu Y, Message SD, Kebadze T, et al. Bronchial mucosal inflammation and illness severity in response to experimental rhinovirus infection in COPD. J Allergy Clin Immunol 2020;146(4):840-50.

7. Wen Y, Reid DW, Zhang D, Ward C, Wood-Baker R, Walters EH. Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD. Int J Chron Obstruct Pulmon Dis 2010;5:327-34.

8. Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, van der Mark TW, Koëter GH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Chest 2000;117(5 Suppl 1):262S.

9. Richter A, O'Donnell RA, Powell RM, Sanders MW, Holgate ST, Djukanovic R, et al. Autocrine ligands for the epidermal growth factor receptor mediate interleukin-8 release from bronchial epithelial cells in response to cigarette smoke. Am J Respir Cell Mol Biol 2002;27(1):85-90.

10. Vernooy JHJ, Lindeman JHN, Jacobs JA, Hanemaaijer R, Wouters EFM. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004;126(6):1802-10.

11. Dentener MA, Louis R, Cloots RHE, Henket M, Wouters EFM. Differences in local versus systemic TNF α production in COPD: inhibitory effect of hyaluronan on LPS induced blood cell TNF α release. Thorax 2006;61(6):478-84.

12. Zuo L, Lucas K, Fortuna CA, Chuang CC, Best TM. Molecular regulation of toll-like receptors in asthma and COPD. Front Physiol 2015;6:312.

13. Freeman CM, Curtis JL. Lung dendritic cells: shaping immune responses throughout chronic obstructive pulmonary disease progression. Am J Respir Cell Mol Biol 2017;56(2):152-9.

14. Ishak A, Ramsay M, Hart N, Steier J. BPAP is an effective second-line therapy for obese patients with OSA failing regular CPAP: a prospective observational cohort study. Respirology 2020;25(4):443-8.

15. Zhou L, Li X, Guan L, Chen J, Guo B, Wu W, et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. Int J Chron Obstruct Pulmon Dis 2017;12:1279.

16. Struik FM, Sprooten RT, Kerstjens HA, Bladder G, Zijnen M, Asin J, et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax 2014;69(9):826-34.

17. Plant PK, Owen JL, Elliott MW. One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administration. Thorax 2000;55(7):550-4.

18. Confalonieri M, Parigi P, Scartabellati A, Aiolfi S, Scorsetti S, Nava S, et al. Noninvasive mechanical ventilation improves the immediate and long-term outcome of COPD patients with acute respiratory failure. Eur Respir J 1996;9(3):422-30.

19. Domej W, Oettl K, Renner W. Oxidative stress and free radicals in COPD–implications and relevance for treatment. Int J Chron Obstruct Pulmon Dis 2014;9:1207-24.

20. Yamamoto C, Yoneda T, Yoshikawa M, Fu A, Tokayama T, Tsukaguchi K, et al. Airway inflammation in COPD assessed by sputum levels of Interleukin-8. Chest 1997;112(2):505-10.

21. Márquez-Martín E, Ruiz FO, Ramos PC, López-Campos JL, Azcona BV, Cortés EB. Randomized trial of noninvasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respir Med 2014;108(12):1741-51.

22. Paone G, Conti V, Biondi-Zoccai G, De Falco E, Chimenti I, Peruzzi M, et al. Long-term home noninvasive mechanical ventilation increases systemic inflammatory response in chronic obstructive pulmonary disease: a prospective observational study. Mediators Inflamm 2014;2014:503145.